Global Bovine Babesiosis Treatment Market

Bovine Babesiosis Treatment Comprehensive Study by Type (Blood Tests, PCR Assays, Serology Tests, Others), Application (Research Laboratories, Veterinary Hospitals, Veterinary Clinics, Animal Care Centers, Others), Vaccine (Live-Attenuated Vaccines, Inactivated Vaccines, Others (Toxoid Vaccines, and Others)), Drug Class (Antiprotozoal Agents, Antibiotics, Others) Players and Region - Global Market Outlook to 2026

Bovine Babesiosis Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Bovine Babesiosis Treatment Market Overview:
Bovine babesiosis is a tick-borne disease of cattle caused by protozoan parasites. It is the most significant arthropod-borne disease of cattle worldwide. Bovine babesiosis causes significant morbidity and mortality. The most prevalent protozoan species that cause the disease are Babesia bovis and B. bigemina. These two species are found throughout all tropical and subtropical regions. Symptoms of the disease usually appear within two to three weeks of tick infestation. Animals infected with Babesia bovis and B. bigemina develop anorexia, high fever, diarrhea or constipation, muscle tremor, hemoglobinuria, etc. Older animals are more affected by this disease. Abortions may occur in pregnant animals severely affected by bovine babesiosis.

Growth Drivers
  • Increase in the Incidence of Babesiosis among Cattle
  • Rising Awareness Regarding Animal Health

Roadblocks
  • Resistance to Antibiotics

Opportunities
  • Technological Development and Advancement in the Bovine Babesiosis Treatment

Challenges
  • Lack of Vaccines that Prevent the Transmission of Babesiosis


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are GlaxoSmithKline, plc (United Kingdom), Merck & Co., Inc. (United States), Limor de Colombia (Colombia), Onderstepoort Biological Products SOC Ltd (South Africa), Letopharm Limited (China), Biogenesis-Bago (Argentina), Heska Corporation (United States), Colorado Serum (United States), Boehringer Ingelheim (Germany), SYVA Laboratorios (Spain) and Lohmann Animal Health (Germany). Considering Market by Vaccine, the sub-segment i.e. Live-Attenuated Vaccines will boost the Bovine Babesiosis Treatment market. Considering Market by Drug Class, the sub-segment i.e. Antiprotozoal Agents will boost the Bovine Babesiosis Treatment market.

What Can be Explored with the Bovine Babesiosis Treatment Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Bovine Babesiosis Treatment Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Bovine Babesiosis Treatment
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Bovine Babesiosis Treatment market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Bovine Babesiosis Treatment market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Bovine Babesiosis Treatment Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Blood Tests
  • PCR Assays
  • Serology Tests
  • Others
By Application
  • Research Laboratories
  • Veterinary Hospitals
  • Veterinary Clinics
  • Animal Care Centers
  • Others
By Vaccine
  • Live-Attenuated Vaccines
  • Inactivated Vaccines
  • Others (Toxoid Vaccines, and Others)

By Drug Class
  • Antiprotozoal Agents
  • Antibiotics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Incidence of Babesiosis among Cattle
      • 3.2.2. Rising Awareness Regarding Animal Health
    • 3.3. Market Challenges
      • 3.3.1. Lack of Vaccines that Prevent the Transmission of Babesiosis
    • 3.4. Market Trends
      • 3.4.1. Upsruging Demand for PCR assays in Laboratories
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bovine Babesiosis Treatment, by Type, Application, Vaccine, Drug Class and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Bovine Babesiosis Treatment (Value)
      • 5.2.1. Global Bovine Babesiosis Treatment by: Type (Value)
        • 5.2.1.1. Blood Tests
        • 5.2.1.2. PCR Assays
        • 5.2.1.3. Serology Tests
        • 5.2.1.4. Others
      • 5.2.2. Global Bovine Babesiosis Treatment by: Application (Value)
        • 5.2.2.1. Research Laboratories
        • 5.2.2.2. Veterinary Hospitals
        • 5.2.2.3. Veterinary Clinics
        • 5.2.2.4. Animal Care Centers
        • 5.2.2.5. Others
      • 5.2.3. Global Bovine Babesiosis Treatment by: Vaccine (Value)
        • 5.2.3.1. Live-Attenuated Vaccines
        • 5.2.3.2. Inactivated Vaccines
        • 5.2.3.3. Others (Toxoid Vaccines, and Others)
      • 5.2.4. Global Bovine Babesiosis Treatment by: Drug Class (Value)
        • 5.2.4.1. Antiprotozoal Agents
        • 5.2.4.2. Antibiotics
        • 5.2.4.3. Others
      • 5.2.5. Global Bovine Babesiosis Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Bovine Babesiosis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline, plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co., Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Limor de Colombia (Colombia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Onderstepoort Biological Products SOC Ltd (South Africa)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Letopharm Limited (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biogenesis-Bago (Argentina)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Heska Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Colorado Serum (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Boehringer Ingelheim (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. SYVA Laboratorios (Spain)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Lohmann Animal Health (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Bovine Babesiosis Treatment Sale, by Type, Application, Vaccine, Drug Class and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Bovine Babesiosis Treatment (Value)
      • 7.2.1. Global Bovine Babesiosis Treatment by: Type (Value)
        • 7.2.1.1. Blood Tests
        • 7.2.1.2. PCR Assays
        • 7.2.1.3. Serology Tests
        • 7.2.1.4. Others
      • 7.2.2. Global Bovine Babesiosis Treatment by: Application (Value)
        • 7.2.2.1. Research Laboratories
        • 7.2.2.2. Veterinary Hospitals
        • 7.2.2.3. Veterinary Clinics
        • 7.2.2.4. Animal Care Centers
        • 7.2.2.5. Others
      • 7.2.3. Global Bovine Babesiosis Treatment by: Vaccine (Value)
        • 7.2.3.1. Live-Attenuated Vaccines
        • 7.2.3.2. Inactivated Vaccines
        • 7.2.3.3. Others (Toxoid Vaccines, and Others)
      • 7.2.4. Global Bovine Babesiosis Treatment by: Drug Class (Value)
        • 7.2.4.1. Antiprotozoal Agents
        • 7.2.4.2. Antibiotics
        • 7.2.4.3. Others
      • 7.2.5. Global Bovine Babesiosis Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bovine Babesiosis Treatment: by Type(USD Million)
  • Table 2. Bovine Babesiosis Treatment Blood Tests , by Region USD Million (2015-2020)
  • Table 3. Bovine Babesiosis Treatment PCR Assays , by Region USD Million (2015-2020)
  • Table 4. Bovine Babesiosis Treatment Serology Tests , by Region USD Million (2015-2020)
  • Table 5. Bovine Babesiosis Treatment Others , by Region USD Million (2015-2020)
  • Table 6. Bovine Babesiosis Treatment: by Application(USD Million)
  • Table 7. Bovine Babesiosis Treatment Research Laboratories , by Region USD Million (2015-2020)
  • Table 8. Bovine Babesiosis Treatment Veterinary Hospitals , by Region USD Million (2015-2020)
  • Table 9. Bovine Babesiosis Treatment Veterinary Clinics , by Region USD Million (2015-2020)
  • Table 10. Bovine Babesiosis Treatment Animal Care Centers , by Region USD Million (2015-2020)
  • Table 11. Bovine Babesiosis Treatment Others , by Region USD Million (2015-2020)
  • Table 12. Bovine Babesiosis Treatment: by Vaccine(USD Million)
  • Table 13. Bovine Babesiosis Treatment Live-Attenuated Vaccines , by Region USD Million (2015-2020)
  • Table 14. Bovine Babesiosis Treatment Inactivated Vaccines , by Region USD Million (2015-2020)
  • Table 15. Bovine Babesiosis Treatment Others (Toxoid Vaccines, and Others) , by Region USD Million (2015-2020)
  • Table 16. Bovine Babesiosis Treatment: by Drug Class(USD Million)
  • Table 17. Bovine Babesiosis Treatment Antiprotozoal Agents , by Region USD Million (2015-2020)
  • Table 18. Bovine Babesiosis Treatment Antibiotics , by Region USD Million (2015-2020)
  • Table 19. Bovine Babesiosis Treatment Others , by Region USD Million (2015-2020)
  • Table 20. South America Bovine Babesiosis Treatment, by Country USD Million (2015-2020)
  • Table 21. South America Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 22. South America Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 23. South America Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 24. South America Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 25. Brazil Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 26. Brazil Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 27. Brazil Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 28. Brazil Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 29. Argentina Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 30. Argentina Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 31. Argentina Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 32. Argentina Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 33. Rest of South America Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 34. Rest of South America Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 35. Rest of South America Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 36. Rest of South America Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 37. Asia Pacific Bovine Babesiosis Treatment, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 39. Asia Pacific Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 40. Asia Pacific Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 41. Asia Pacific Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 42. China Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 43. China Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 44. China Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 45. China Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 46. Japan Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 47. Japan Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 48. Japan Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 49. Japan Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 50. India Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 51. India Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 52. India Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 53. India Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 54. South Korea Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 55. South Korea Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 56. South Korea Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 57. South Korea Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 58. Taiwan Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 59. Taiwan Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 60. Taiwan Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 61. Taiwan Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 62. Australia Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 63. Australia Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 64. Australia Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 65. Australia Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 70. Europe Bovine Babesiosis Treatment, by Country USD Million (2015-2020)
  • Table 71. Europe Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 72. Europe Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 73. Europe Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 74. Europe Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 75. Germany Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 76. Germany Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 77. Germany Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 78. Germany Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 79. France Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 80. France Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 81. France Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 82. France Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 83. Italy Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 84. Italy Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 85. Italy Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 86. Italy Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 87. United Kingdom Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 88. United Kingdom Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 89. United Kingdom Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 90. United Kingdom Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 91. Netherlands Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 92. Netherlands Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 93. Netherlands Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 94. Netherlands Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 95. Rest of Europe Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 96. Rest of Europe Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 97. Rest of Europe Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 98. Rest of Europe Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 99. MEA Bovine Babesiosis Treatment, by Country USD Million (2015-2020)
  • Table 100. MEA Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 101. MEA Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 102. MEA Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 103. MEA Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 104. Middle East Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 105. Middle East Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 106. Middle East Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 107. Middle East Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 108. Africa Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 109. Africa Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 110. Africa Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 111. Africa Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 112. North America Bovine Babesiosis Treatment, by Country USD Million (2015-2020)
  • Table 113. North America Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 114. North America Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 115. North America Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 116. North America Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 117. United States Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 118. United States Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 119. United States Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 120. United States Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 121. Canada Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 122. Canada Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 123. Canada Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 124. Canada Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 125. Mexico Bovine Babesiosis Treatment, by Type USD Million (2015-2020)
  • Table 126. Mexico Bovine Babesiosis Treatment, by Application USD Million (2015-2020)
  • Table 127. Mexico Bovine Babesiosis Treatment, by Vaccine USD Million (2015-2020)
  • Table 128. Mexico Bovine Babesiosis Treatment, by Drug Class USD Million (2015-2020)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Bovine Babesiosis Treatment: by Type(USD Million)
  • Table 141. Bovine Babesiosis Treatment Blood Tests , by Region USD Million (2021-2026)
  • Table 142. Bovine Babesiosis Treatment PCR Assays , by Region USD Million (2021-2026)
  • Table 143. Bovine Babesiosis Treatment Serology Tests , by Region USD Million (2021-2026)
  • Table 144. Bovine Babesiosis Treatment Others , by Region USD Million (2021-2026)
  • Table 145. Bovine Babesiosis Treatment: by Application(USD Million)
  • Table 146. Bovine Babesiosis Treatment Research Laboratories , by Region USD Million (2021-2026)
  • Table 147. Bovine Babesiosis Treatment Veterinary Hospitals , by Region USD Million (2021-2026)
  • Table 148. Bovine Babesiosis Treatment Veterinary Clinics , by Region USD Million (2021-2026)
  • Table 149. Bovine Babesiosis Treatment Animal Care Centers , by Region USD Million (2021-2026)
  • Table 150. Bovine Babesiosis Treatment Others , by Region USD Million (2021-2026)
  • Table 151. Bovine Babesiosis Treatment: by Vaccine(USD Million)
  • Table 152. Bovine Babesiosis Treatment Live-Attenuated Vaccines , by Region USD Million (2021-2026)
  • Table 153. Bovine Babesiosis Treatment Inactivated Vaccines , by Region USD Million (2021-2026)
  • Table 154. Bovine Babesiosis Treatment Others (Toxoid Vaccines, and Others) , by Region USD Million (2021-2026)
  • Table 155. Bovine Babesiosis Treatment: by Drug Class(USD Million)
  • Table 156. Bovine Babesiosis Treatment Antiprotozoal Agents , by Region USD Million (2021-2026)
  • Table 157. Bovine Babesiosis Treatment Antibiotics , by Region USD Million (2021-2026)
  • Table 158. Bovine Babesiosis Treatment Others , by Region USD Million (2021-2026)
  • Table 159. South America Bovine Babesiosis Treatment, by Country USD Million (2021-2026)
  • Table 160. South America Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 161. South America Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 162. South America Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 163. South America Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 164. Brazil Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 165. Brazil Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 166. Brazil Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 167. Brazil Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 168. Argentina Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 169. Argentina Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 170. Argentina Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 171. Argentina Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 172. Rest of South America Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 173. Rest of South America Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 174. Rest of South America Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 175. Rest of South America Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 176. Asia Pacific Bovine Babesiosis Treatment, by Country USD Million (2021-2026)
  • Table 177. Asia Pacific Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 178. Asia Pacific Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 179. Asia Pacific Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 180. Asia Pacific Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 181. China Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 182. China Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 183. China Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 184. China Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 185. Japan Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 186. Japan Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 187. Japan Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 188. Japan Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 189. India Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 190. India Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 191. India Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 192. India Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 193. South Korea Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 194. South Korea Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 195. South Korea Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 196. South Korea Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 197. Taiwan Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 198. Taiwan Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 199. Taiwan Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 200. Taiwan Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 201. Australia Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 202. Australia Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 203. Australia Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 204. Australia Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 209. Europe Bovine Babesiosis Treatment, by Country USD Million (2021-2026)
  • Table 210. Europe Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 211. Europe Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 212. Europe Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 213. Europe Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 214. Germany Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 215. Germany Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 216. Germany Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 217. Germany Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 218. France Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 219. France Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 220. France Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 221. France Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 222. Italy Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 223. Italy Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 224. Italy Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 225. Italy Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 226. United Kingdom Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 227. United Kingdom Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 228. United Kingdom Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 229. United Kingdom Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 230. Netherlands Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 231. Netherlands Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 232. Netherlands Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 233. Netherlands Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 234. Rest of Europe Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 235. Rest of Europe Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 236. Rest of Europe Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 237. Rest of Europe Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 238. MEA Bovine Babesiosis Treatment, by Country USD Million (2021-2026)
  • Table 239. MEA Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 240. MEA Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 241. MEA Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 242. MEA Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 243. Middle East Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 244. Middle East Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 245. Middle East Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 246. Middle East Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 247. Africa Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 248. Africa Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 249. Africa Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 250. Africa Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 251. North America Bovine Babesiosis Treatment, by Country USD Million (2021-2026)
  • Table 252. North America Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 253. North America Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 254. North America Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 255. North America Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 256. United States Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 257. United States Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 258. United States Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 259. United States Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 260. Canada Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 261. Canada Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 262. Canada Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 263. Canada Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 264. Mexico Bovine Babesiosis Treatment, by Type USD Million (2021-2026)
  • Table 265. Mexico Bovine Babesiosis Treatment, by Application USD Million (2021-2026)
  • Table 266. Mexico Bovine Babesiosis Treatment, by Vaccine USD Million (2021-2026)
  • Table 267. Mexico Bovine Babesiosis Treatment, by Drug Class USD Million (2021-2026)
  • Table 268. Research Programs/Design for This Report
  • Table 269. Key Data Information from Secondary Sources
  • Table 270. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bovine Babesiosis Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Bovine Babesiosis Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global Bovine Babesiosis Treatment: by Vaccine USD Million (2015-2020)
  • Figure 7. Global Bovine Babesiosis Treatment: by Drug Class USD Million (2015-2020)
  • Figure 8. South America Bovine Babesiosis Treatment Share (%), by Country
  • Figure 9. Asia Pacific Bovine Babesiosis Treatment Share (%), by Country
  • Figure 10. Europe Bovine Babesiosis Treatment Share (%), by Country
  • Figure 11. MEA Bovine Babesiosis Treatment Share (%), by Country
  • Figure 12. North America Bovine Babesiosis Treatment Share (%), by Country
  • Figure 13. Global Bovine Babesiosis Treatment share by Players 2020 (%)
  • Figure 14. Global Bovine Babesiosis Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Bovine Babesiosis Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline, plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline, plc (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Limor de Colombia (Colombia) Revenue, Net Income and Gross profit
  • Figure 22. Limor de Colombia (Colombia) Revenue: by Geography 2020
  • Figure 23. Onderstepoort Biological Products SOC Ltd (South Africa) Revenue, Net Income and Gross profit
  • Figure 24. Onderstepoort Biological Products SOC Ltd (South Africa) Revenue: by Geography 2020
  • Figure 25. Letopharm Limited (China) Revenue, Net Income and Gross profit
  • Figure 26. Letopharm Limited (China) Revenue: by Geography 2020
  • Figure 27. Biogenesis-Bago (Argentina) Revenue, Net Income and Gross profit
  • Figure 28. Biogenesis-Bago (Argentina) Revenue: by Geography 2020
  • Figure 29. Heska Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Heska Corporation (United States) Revenue: by Geography 2020
  • Figure 31. Colorado Serum (United States) Revenue, Net Income and Gross profit
  • Figure 32. Colorado Serum (United States) Revenue: by Geography 2020
  • Figure 33. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 35. SYVA Laboratorios (Spain) Revenue, Net Income and Gross profit
  • Figure 36. SYVA Laboratorios (Spain) Revenue: by Geography 2020
  • Figure 37. Lohmann Animal Health (Germany) Revenue, Net Income and Gross profit
  • Figure 38. Lohmann Animal Health (Germany) Revenue: by Geography 2020
  • Figure 39. Global Bovine Babesiosis Treatment: by Type USD Million (2021-2026)
  • Figure 40. Global Bovine Babesiosis Treatment: by Application USD Million (2021-2026)
  • Figure 41. Global Bovine Babesiosis Treatment: by Vaccine USD Million (2021-2026)
  • Figure 42. Global Bovine Babesiosis Treatment: by Drug Class USD Million (2021-2026)
  • Figure 43. South America Bovine Babesiosis Treatment Share (%), by Country
  • Figure 44. Asia Pacific Bovine Babesiosis Treatment Share (%), by Country
  • Figure 45. Europe Bovine Babesiosis Treatment Share (%), by Country
  • Figure 46. MEA Bovine Babesiosis Treatment Share (%), by Country
  • Figure 47. North America Bovine Babesiosis Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline, plc (United Kingdom)
  • Merck & Co., Inc. (United States)
  • Limor de Colombia (Colombia)
  • Onderstepoort Biological Products SOC Ltd (South Africa)
  • Letopharm Limited (China)
  • Biogenesis-Bago (Argentina)
  • Heska Corporation (United States)
  • Colorado Serum (United States)
  • Boehringer Ingelheim (Germany)
  • SYVA Laboratorios (Spain)
  • Lohmann Animal Health (Germany)
Select User Access Type

Key Highlights of Report


Jun 2021 250 Pages 81 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Bovine Babesiosis Treatment Market Quantitative research analysis
Global Bovine Babesiosis Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Bovine Babesiosis Treatment market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Bovine Babesiosis Treatment market are GlaxoSmithKline, plc (United Kingdom), Merck & Co., Inc. (United States), Limor de Colombia (Colombia), Onderstepoort Biological Products SOC Ltd (South Africa), Letopharm Limited (China), Biogenesis-Bago (Argentina), Heska Corporation (United States), Colorado Serum (United States), Boehringer Ingelheim (Germany), SYVA Laboratorios (Spain) and Lohmann Animal Health (Germany), to name a few.
"Upsruging Demand for PCR assays in Laboratories" is seen as one of major influencing trends for Bovine Babesiosis Treatment Market during projected period 2020-2026.

Know More About Global Bovine Babesiosis Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Breast Lumpectomy Treatment Comprehensive Study by Treatment (Stage I Breast Cancer, Stage II Breast Cancer, DCIS (Ductal Carcinoma in Situ)), End User (Research Institutes and Academic Centers, Hosp...
$ 3450
Aortic Aneurysm Comprehensive Study by Type (Abdominal Aortic Aneurysm (AAA), Thoracic Aortic Aneurysm (TAA)), Application (Ambulatory Surgical Centers, Hospital), Treatment (Endovascular Aneurysm Re...
$ 3500
Retinitis Pigmentosa Comprehensive Study by Treatment (Acetazolamide Medication, Vitamin A palmitate, Retinal implant, Sunglasses), End-users (Hospitals, Clinics, Others), Diagnosis (Genetic Testing,...
$ 3750
Skin Neoplasms Comprehensive Study by Type (Benign Neoplasms, Malignant Neoplasms), Treatment (Chemotherapy, Surgery, Non-Invasive Treatments, Others), End User (Hospital and Clinics, Diagnostic Cent...
$ 3750
Transient Ischemic Attack Comprehensive Study by End Users (Hospitals & Clinics, Diagnostic Centers, Research Laboratories), Age Group (0–18 years, 19–40 years, 41–60 years, 60+ years), Diagnosis Typ...
$ 3750
Limb Girdle Muscular Dystrophy Comprehensive Study by Type (LGMD1, LGMD2), Application (Hospitals, Clinics, Others), Treatment Type (Occupational Therapy, Respiratory Therapy, Speech Therapy), Diagno...
$ 3350